| Literature DB >> 29518011 |
Ana Rey-Rico1,2, Magali Cucchiarini3.
Abstract
Lineal (poloxamers or Pluronic®) or X-shaped (poloxamines or Tetronic®) amphiphilic tri-block copolymers of poly(ethylene oxide) and poly(propylene oxide) (PEO-PPO-PEO) have been broadly explored for controlled drug delivery in different regenerative medicine approaches. The ability of these copolymers to self-assemble as micelles and to undergo sol-to-gel transitions upon heating has endowed the denomination of "smart" or "intelligent" systems. The use of PEO-PPO-PEO copolymers as gene delivery systems is a powerful emerging strategy to improve the performance of classical gene transfer vectors. This review summarizes the state of art of the application of PEO-PPO-PEO copolymers in both nonviral and viral gene transfer approaches and their potential as gene delivery systems in different regenerative medicine approaches.Entities:
Keywords: PEO-PPO-PEO copolymers; gene transfer; nonviral vectors; viral vectors
Mesh:
Substances:
Year: 2018 PMID: 29518011 PMCID: PMC5877636 DOI: 10.3390/ijms19030775
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure of poloxamers (A) and poloxamines (B). Two-dimensional sequences of Poloxamer P85 (CID: 10145203) and poloxamine 304 (CID: 86278173) were obtained from PubChem. Three-dimensional (3D) structures of the different compounds were drawn with ChemBioOffice 2012 (Chem3D Pro 13; PerkinElmer Informatics, Cambrigde, MA, USA).
Use of PEO-PPO-PEO copolymers for nonviral gene transfer.
| Nonviral Systems | Copolymers | Genes | Targets | Administration | Observations | References |
|---|---|---|---|---|---|---|
| pDNA | SP1017: Pluronic® L61 + F127 | muscle | i.m. (rat) | 10-fold increased trangene expression | [ | |
| increased transgene expression after electroporation | [ | |||||
| PE6400 | muscle | cranial muscle (mouse) | long-term expression similar to electrotransfer | [ | ||
| Pluronic® F68 and F127 | n.s. | in vitro BL-6 cells | increased activity in transfecting cells in the presence of 20% serum | [ | ||
| Pluronic® P85 and L61 | n.s. | in vitro NIH3T3, C2C12 and Cl66 cells | increased transgene expression | [ | ||
| PEO-PPO-PEO copolymers average MW 8400 | Eye | ocular (rabbit, mouse) | higher transgene expression at 2 and 3 days | [ | ||
| Polycation DNA and poly( | Pluronic® P85 | CAT | n.s. | in vitro NIH 3T3, MDCK, and Jurkat cell lines | enhanced transfection | [ |
| P123- | Pluronic® P123 | n.s. | in vitro Cos-7 cells, i.v. (mouse) | more uniform distribution of transgene, significant improvement of gene expression in liver | [ | |
| n.s. | in vitro prostate cancer cells (PC-3) | optimization of polyplexe size | [ | |||
| PEI-DNA complex | Pluronic® F68, F127, P105, P94, L122, L61 | n.s. | in vitro NIH/3T3 cells | Pluronic® with higher HLB showed marked improvement of gene expression levels in serum media compared with PEI-DNA complexes alone | [ | |
| PEI-DNA complex or pDNA | Tetronic® 904 | GFP | n.s. | in vitro N2A cells | sustained transgene expression for over 2 weeks | [ |
| PLL- | Pluronic® F127 | n.s. | in vitro HeLa cells | higher transfection efficiency with polymer:DNA at 1:1 | [ |
Abbreviations: pDNA: plasmid DNA; lacZ: E. coli β-galactosidase; luc: luciferase; PE6400: poly(ethyleneoxide)(13)-poly(propyleneoxide)(30)-poly(ethyleneoxide)(13) block copolymer; n.s.: not specified; GFP: green fluorescent protein; CAT: chloramphenicol acetyltransferase; i.m.: intramuscular; i.v.: intravenous; P123-g-PEI(2K)polyplexe: Pluronic® 123 grafted with 2KDa polyethyleneimine; PEI-DNA complex: polyethyleneimine-DNA complex; PLL-g-Pluronic®: poly-l-lysine grafted with Pluronic®.
Use of PEO-PPO-PEO copolymers for viral gene transfer (part I).
| Viral Systems | Copolymers | Genes | Targets | Administration | Observations | References |
|---|---|---|---|---|---|---|
| Adenovirus | Pluronic® F127 | cardiovascular | in vitrovascular smooth muscle cells | high pericellular concentrations of vector and 10- to 100-fold increase of transduction | [ | |
| Pluronic® F127 | vascular | in vitrovascular smooth muscle cells; in vivo balloon injured carotid arteries (rat) | improved gene transfer efficiencies | [ | ||
| Pluronic® F127 | vascular | in vivo percutaneous administration in iliac arteries (rabbit) | increased efficacy of percutaneous gene transfer and reduced transfection time | [ | ||
| Pluronic® F127 | vascular | in vivo external iliac artery with channel balloon catheter | [ | |||
| Pluronic® F127 | GFP, | solid tumors | in vivo intratumoral infusion (mouse) | blocked convection of viral vectors in the interstitial space and the lumen of microvessels in the vicinity of the infusion site | [ | |
| Lentivirus | Pluronic® F127 | GFP | CNS | in vivo injection to the thalamus (rat) | increased transduction of astrocytes at injection site | [ |
| Pluronic® F108 | GFP, | n.s. | in vitro HEK293T, KARPAS-299, SUDHL-1, SR-786, SUP-M2, and PANC-1 cell lines | specific contribution to efficiency of each adjuvant; polybrene: charge protector and poloxamer synperonic F108: membrane modulator | [ |
Abbreviations: lacZ: E. coli β-galactosidase; luc: luciferase; gax: growth arrest homeobox; GFP: green fluorescent protein; rAAV: recombinant adeno-associated viral vectors; CNS: central nervous system; DC: dendritic cells; n.s.: not specified.
Use of PEO-PPO-PEO copolymers for viral gene transfer (part II).
| Viral Systems | Copolymers | Genes | Targets | Administration | Observations | References |
|---|---|---|---|---|---|---|
| rAAV | Pluronic® F127 | GM-CSF | solid tumors | in vivo intratumoral infusion (mouse) | higher efficiency by combining DC, local tumor irradiation and controlled supply of recombinant mGM-CSF with Pluronic® | [ |
| Pluronic® F68 | adipose tissue | in vivo inguinal (mouse) | increased transgene expression after 4 weeks | [ | ||
| Pluronic® F127 | cartilage | in vitro hMSCs | controlled release of rAAV for high efficiencies over time and gene expression levels similar to those achieved by direct vector application | [ | ||
| Pluronic® F68, Tetronic® 908 | RFP, | cartilage | in vitro hMSCs | encapsulation of rAAV in polymeric micelles for effective, durable, and safe modification of hMSCs; restoration of hMSC transduction in conditions of gene transfer inhibition; effective chondrogenesis | [ | |
| Pluronic® F68, Tetronic® 908 | cartilage | in vitro hOACs in situ human osteochondral model | micellar encapsulation for increased stability and bioactivity of rAAV; high levels of safe transgene expression in vitro and in experimental osteochondral defects in situ | [ | ||
| Pluronic® F68, Tetronic® 908 | TGF-β | cartilage | in vitro hOACs in situ human osteochondral model | increased levels of transgene expression compared with free vector treatment; high proteoglycan deposition and increased cell numbers in hOACs in vitro; high deposition of type-II collagen and reduced hypertrophy in osteochondral defects models in situ | [ | |
| Pluronic® F68, Tetronic® 908 | cartilage | in vitro hMSCs | high concentrations of rAAV; sustained levels of transgene expression over time | [ |
Abbreviations: rAAV: recombinant adeno-associated viral vectors; lacZ: E. coli β-galactosidase; GM-CSF: granulocyte-macrophage colony-stimulating factor; hMSCs: human mesenchymal stem cells; RFP: red fluorescent protein; SOX9: sex-determining region Y-type high mobility group box 9; hOACs: human osteochondral chondrocytes; TGF-β: transforming growth factor beta.